The DOI matches its Crossref record.
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Abstract
Non-alcoholic fatty liver disease is highly prevalent in overweight and obese children and adults. It progresses to steatohepatitis (with raised liver transaminase levels) and fibrosis, and eventually to cirrhosis. Detecting this, excluding other causes of liver disease, and monitoring its progress takes up much resource in the obesity clinic. But, frustratingly, there are currently no effective treatments, other than weight loss. The hormone fibroblast growth factor 19 (FGF19) is produced by the gut in response to absorption of bile acids and it acts on hepatocytes via the receptor functional growth factor receptor 4 (FGFR4). Here, it is shown to markedly reduce liver fat content, steatohepatitis, and non-invasive serum biomarkers of fibrosis, probably by acting on multiple pathogenic pathways. FGF19 is a potent inhibitor of bile acid synthesis and inhibits fatty acid synthesis and de novo lipogenesis. Recent data show that FGF19 also decreases markers of hepatic inflammation, and improves markers of fibrosis in patients with primary sclerosing cholangitis. There were concerns that endogenous FGF19 also confers hepatocellular carcinoma, but so far the engineered FGF19 analogue, NGM282, appears to be non-tumorigenic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Dietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., Abdelmalek, M. F., & Suzuki, A. (2019) · Hepatology · doi:10.1002/hep.30626 · Cited by 1,050
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Metadata
- Authors
- SA, H., ME, R., MF, A., JF, T., AH, P., HL, A., M, K., MR, B., MJ, J., L, L., SJ, R., AM, D., & R, L.
- Venue
- Yearbook of Paediatric Endocrinology
- Publisher
- Bioscientifica
- Published
- 2018-09-11
- ISSN
- 1662-3991 (ISSN-L)
- 1662-4009
- OpenAlex
- W2900274665
- Cited by
- 188
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. https://app.cochat.ai/papers/10.1530/ey.15.15.7
- The paper
- SA, H., ME, R., MF, A., JF, T., AH, P., HL, A., M, K., MR, B., MJ, J., L, L., SJ, R., AM, D., & R, L. (2018). NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Yearbook of Paediatric Endocrinology. https://doi.org/10.1530/ey.15.15.7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.